BRAF and melanoma: Nonetheless, in the clinical setting, patients with BRAF-V600 melanoma often switch to a different BRAFi/MEKi combination, such as D/T or encorafenib/binimetinib (E/B), after progressing or experiencing toxicity with a prior BRAFi/MEKi treatment course, either D/T, E/B, or vemurafenib/cobimetinib.